Abstract:Cancer stem cells (CSCs) are a small population of undifferentiated cancer cells within tumors, which contribute to tumorigenicity and relapse. In the current study, CD133 (also termed prominin-1), a CSC marker, was investigated to determine its involvement in predicting carcinogenesis and prognosis in patients with non-small cell lung carcinoma (NSCLC). CD133-positive lung cancer cells were isolated to analyze self-renewal, differentiation and tumorigenic abilities in vitro and in vivo. Quantitative polymerase chain reaction was used to detect the expression of CD133 and three other CSC-associated markers, octamer-binding transcription factor 4 (OCT4A), Nanog homeobox (NANOG) and multidrug resistance protein 1 (MDR1), in primary NSCLC and adjacent non-cancer tissues. A series of statistical methods were used to analyze the correlation between mRNA expression levels, clinicopathological features and patient survival. The results showed that CD133-positive NSCLC cells demonstrated clonogenic, tumorigenic and drug-resistance properties compared with their CD133-negative counterparts or parental cells. In addition, compared with the adjacent normal lung tissue, the levels of CSC-associated biomarkers CD133, OCT4A, NANOG and MDR1 were significantly increased in NSCLC tissue. Elevated expression of CD133 was associated with stage, tumor size and differentiation of NSCLC; however, the cox hazard regression analysis showed no significant association between CD133 expression and overall patient survival. The present study supports the hypothesis that the stem cell population can be enriched in cells expressing the CD133 cell surface marker and that highly expressed CD133 is involved in the occurrence of NSCLC. However, CD133 may not be considered as an independent factor in predicting the prognosis of patients with NSCLC. Further studies are required to investigate the association between CD133 expression and overall patient survival.

Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: a case report

Quantitative Analyses of CD133 Expression Facilitate Researches on Tumor Stem Cells.

Aberrant signal transduction in Indian triple-negative breast cancer patients

Prognostic significance of cancer stem cell marker CD 133 expression in breast cancer

Regulation of cancer stem cells in triple negative breast cancer

CD133 as a marker for cancer stem cells: progresses and concerns.

High CD133 Expression in the Nucleus and Cytoplasm Predicts Poor Prognosis in Non-Small Cell Lung Cancer

Cancer Stem Cell Marker CD133+ Tumour Cells and Clinical Outcome in Rectal Cancer

Single cell profile of tumor and immune cells in primary triple-negative breast cancer and different sites in the axillary lymph nodes.

CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy

Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments

Transcriptional Profiles of Different States of Cancer Stem Cells in Triple-Negative Breast Cancer

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells

CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer

Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer

CD133: a cancer stem cells marker, is used in colorectal cancers.

CD133 Mrna May Be a Suitable Prognostic Marker for Human Breast Cancer

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Identification of a NACC1-Regulated Gene Signature Implicated in the Features of Triple-Negative Breast Cancer

Spatial and Compositional Biomarkers in Tumor Microenvironment Predicts Clinical Outcomes in Triple-Negative Breast Cancer

New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation